(NASDAQ: IMTX) Immatics Nv's forecast annual revenue growth rate of -14.36% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Immatics Nv's revenue in 2025 is $161,964,044.On average, 2 Wall Street analysts forecast IMTX's revenue for 2025 to be $7,737,883,759, with the lowest IMTX revenue forecast at $6,821,395,484, and the highest IMTX revenue forecast at $8,654,372,033. On average, 2 Wall Street analysts forecast IMTX's revenue for 2026 to be $7,492,960,168, with the lowest IMTX revenue forecast at $6,821,395,484, and the highest IMTX revenue forecast at $8,164,524,852.
In 2027, IMTX is forecast to generate $14,409,772,535 in revenue, with the lowest revenue forecast at $14,409,772,535 and the highest revenue forecast at $14,409,772,535.